10 Things Worth Pay...
Health Care: Drugs
CytRx Corporation (CYTR: NASDAQ)
$3.58 -0.30 | -7.73%
06/04/12 - 04:00 PM ET
Ratio Comparisons
| Company | Industry | S&P 500 | |
| Valuation Ratios | |||
|---|---|---|---|
| P/E Ratio (TTM) | n.a. | 75.30 | 17.70 |
| P/E High - Last 5 Yrs | n.a. | n.a. | 67.70 |
| P/E Low - Last 5 Yrs | n.a. | n.a. | 12.50 |
| Beta | 1.21 | 0.58 | 0.98 |
| Price to Sales (TTM) | 329.08 | 4.62 | 1.42 |
| Price to Book (MRQ) | 5.70 | 3.44 | 2.41 |
| Price to Tangible Book (MRQ) | 5.77 | 6.74 | 5.08 |
| Price to Cash Flow (TTM) | -4.50 | 26.10 | 9.80 |
| Price to Free Cash Flow (TTM) | -4.80 | 48.80 | 17.40 |
| Dividends | |||
| Dividend Yield (%) | 0.00 | 0.50 | 2.10 |
| Dividend Yield - 5 Yr Avg (%) | n.a. | 0.20 | 2.20 |
| Dividend 5 Yr Growth Rate (%) | n.a. | n.a. | -0.76 |
| Payout Ratio (TTM) | 0.00 | 3.00 | 30.00 |
| Sales (MRQ) vs Qtr 1 Yr Ago (%) | n.a. | 9.90 | 11.80 |
| Sales (TTM) vs TTM 1 Yr Ago (%) | 150.00 | 7.70 | 9.20 |
| Growth Rates (%) | |||
| Sales - 5 Yr Growth Rate (%) | -53.04 | 9.03 | 1.79 |
| EPS (MRQ) vs Qtr 1 Yr Ago (%) | n.a. | 18.50 | 17.50 |
| EPS (TTM) vs TTM 1 Yr Ago (%) | n.a. | 18.50 | 17.50 |
| EPS - 5 Yr Growth Rate (%) | n.a. | n.a. | -1.66 |
| Capital Spending - 5 Yr Growth Rate (%) | n.a. | -4.13 | -1.17 |
| Financial Strength | |||
| Quick Ratio (MRQ) | 1.70 | 2.90 | 1.10 |
| Current Ratio (MRQ) | 1.70 | 3.50 | 1.60 |
| LT Debt to Equity (MRQ) | 0.00 | 0.41 | 0.82 |
| Total Debt to Equity (MRQ) | 0.00 | 0.45 | 0.96 |
| Interest Coverage (TTM) | n.a. | 6.20 | 5.50 |
| Profitability Ratios (%) | |||
| Gross Margin (TTM) | n.a. | 84.10 | 46.90 |
| Gross Margin - 5 Yr Avg | n.a. | 83.50 | 47.70 |
| EBITD Margin (TTM) | n.a. | 27.30 | 18.90 |
| EBITD - 5 Yr Avg | -463.77 | 0.00 | 0.00 |
| Pre-Tax Margin (TTM) | n.a. | 14.10 | 12.10 |
| Pre-Tax Margin - 5 Yr Avg | n.a. | 10.60 | 10.30 |
| Management Effectiveness (%) | |||
| Net Profit Margin (TTM) | -73.14 | 0.10 | 0.09 |
| Net Profit Margin - 5 Yr Avg | n.a. | 5.30 | 7.00 |
| Return on Assets (TTM) | -54.80 | 4.70 | 3.10 |
| Return on Assets - 5 Yr Avg | -33.50 | 2.20 | 2.50 |
| Return on Investment (TTM) | -126.00 | 6.10 | 7.90 |
| Return on Investment - 5 Yr Avg | -48.70 | 2.80 | 6.50 |
| Efficiency | |||
| Revenue/Employee (TTM) | 16,667.00 | 701,747.00 | 449,376.00 |
| Net Income/Employee (TTM) | -121,894.00 | 83,589.00 | 39,003.00 |
| Receivable Turnover (TTM) | 0.80 | 5.80 | 7.60 |
| Inventory Turnover (TTM) | n.a. | 1.30 | 8.30 |
| Asset Turnover (TTM) | 0.00 | 0.40 | 0.40 |
Portfolios with CYTR
- Portfolio NameUser Type
- Uservlady 1
- Contributor5 Stocks Under-$10 Setting ...
- UserHope For The Best
- Userrick epple
- ContributorBarron's Research Reports 1...
- UserNat's
- UserHi Potential
- Usernewintrade Portfolio 1
- Usersteveandvickie Portfolio 1
- Useractive-jrd
Latest CYTR Headlines from TheStreet
- 5 Stocks Under $10 With Big Upside Potential 11.18.11 | 06:11 am
- SeaChange, Tenet: Early Volume Plays 12.03.09 | 08:12 am
- CytRx: FDA Lifts 2-year Hold On Arimoclomol Tests 12.02.09 | 09:12 am
- Correction: CytRx FDA Letter 09.09.09 | 04:09 pm
- CytRx Expects To File FDA Response In 4Q 09.08.09 | 10:09 am
- CytRx Rises On Preclinical Data For Stroke Drug 08.24.09 | 01:08 pm
- Movers Roundup: Massey Energy, MannKind 06.08.09 | 02:06 pm
- CytRx Rises On Analyst's 'Outperform' Rating 06.08.09 | 01:06 pm
- Biotech Notebook: Nastech, Amgen, PDL BioPharma 11.15.07 | 04:11 pm
- Wednesday's Health Winners & Losers 11.14.07 | 03:11 pm
Press Releases for CYTR
- CytRx To Hold Conference Call Today At 10:00 A.m. Eastern Time To Discuss Favorable Results From INNO-206 Clinical Trial In Soft Tissue Sarcoma - Business Wire 06.04.12 | 08:06 am
- CytRx Announces Favorable Results From Phase 1b/2 Clinical Trial With INNO-206 - Business Wire 06.03.12 | 09:06 am
- CytRx Regains NASDAQ Compliance - Business Wire 06.01.12 | 08:06 am
- CytRx Announces The Publication Of INNO-206 Findings In Multiple Myeloma In Clinical Cancer Research - Business Wire 05.29.12 | 08:05 am
- CytRx Initiates Phase 2 Clinical Trial With INNO-206 In Pancreatic Cancer - Business Wire 04.26.12 | 08:04 am
- CytRx Receives NASDAQ Extension - Business Wire 04.23.12 | 08:04 am
- CytRx Announces Issuance Of Key U.S. Patent Covering INNO-206 Linker Technology - Business Wire 04.12.12 | 08:04 am
- CytRx’s INNO-206 To Be Featured In Two Presentations At The American Association For Cancer Research (AACR) 2012 Annual Meeting - Business Wire 03.27.12 | 08:03 am
- CytRx Reports 2011 Financial Results - Business Wire 03.13.12 | 08:03 am
- CytRx To Present At The Roth Capital Partners Annual OC Growth Stock Conference - Business Wire 03.05.12 | 08:03 am
Partner Headlines for CYTR
- Biotechs to Watch at the 2012 San Francisco Healthcare Confrences - Analyst Blog - Zacks 01.09.12 | 07:01 am
- Why CytRx Corporation Is Still A Big Biotech 'If' Play - Seeking Alpha 12.14.11 | 09:12 am
- CytRx Is Poised For Growth - Analyst Blog - Zacks 08.13.11 | 12:08 am
- CytRx Reports 2Q 2011 Results - Analyst Blog - Zacks 08.12.11 | 06:08 pm
- As the Market Dips, It's Time to Look for Biotech Sector Deals - Seeking Alpha 06.12.11 | 09:06 am
- CytRx Completes Sale of Molecular Chaperone Assets - Analyst Blog - Zacks 05.17.11 | 09:05 am
- Company News for April 29, 2011 - Corporate Summary - Zacks 04.29.11 | 10:04 am
- Stocks Mixed at Session's Half on Slowing Q1 Economy; Crude Futures Advance - NASDAQ 04.28.11 | 04:04 pm
- Mid-Day Update: Stocks Mixed as GDP Data Weighs; Jobless Claims Rise - NASDAQ 04.28.11 | 04:04 pm
- China Analyst: 10 Pharma Stocks With Highest Growth Potential - Seeking Alpha 10.08.10 | 06:10 am
